Immunotherapy for Infectious Diseases

216 Jacobson
59. Yoshiyama H, Mo H, Moore JP, Ho DD. Characterization of mutants of human immunodeficiency
virus type 1 that have escaped neutralization by a monoclonal antibody to the
gp120 V2 loop. J Virol 1994; 68:974–978.
60. Shotton C, Arnold C, Sattentau Q, Sodroski J, McKeating JA. Identification and characterization
of monoclonal antibodies specific for polymorphic antigenic determinants within
the V2 region of the human immunodeficiency virus type I. J Virol 1995; 69:222–230.
61. Daar ES, Li XL, Mougdil T, Ho DD. High concentrations of recombinant soluble CD4
are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc
Natl Acad Sci USA 1990; 87:6574–6578.
62. Daar ES, Ho DD. Relative resistance of primary HIV-1 isolates to neutralization by soluble
CD4. Am J Med 1991; 90(Suppl 4A):22S–26S.
63. Schacker T, Coombs RW, Collier AC, et al. The effects of high-dose recombinant soluble
CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis 1994; 169:37–40.
64. Hodges TL, Kahn JO, Kaplan LD, et al. Phase I study of recombinant human CD4immunoglobulin
G therapy of patients with AIDS and AIDS-related complex. Antimicrob
Agents Chemother 1991; 35:2580–2586.
65. Gauduin MC, Allaway GP, Maddon PJ, Barbas CF, Burton DR, Koup RA. Evaluation of
the protective role of two recombinant immunoglobulin molecules in passive protection
against primary isolates of HIV-1. Keystone Symposium: Immunopathogenesis of HIV
Infection 1996; Hilton Head Island, South Carolina.
66. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The
CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
Nature 1984; 312:763–767.
67. Klatzman D, Champagne E, Chamaret S, et al. T-lymphocytes T4 molecule behaves as the
receptor for human retrovirus LAV. Nature 1984; 312:767–768.
68. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JKA. (1986) Binding
of HTL-III/LAV to T4� T cells by complex of the 110K viral protein and the T4 molecule.
Science 1986; 231:382–385.
69. Reimann KA, Burkly LC, Burrus B, Waite BCD, Lord CI, Letvin NL. (1993) In vivo
administration to rhesus monkeys of a CD-4 specific monoclonal antibody capable of
blocking AIDS virus replication. AIDS Res Hum Retroviruses 1993; 9:199–207.
70. Reimann KA, Lin WU, Bixler S, et al. A humanized form of a CD4-specific monoclonal
antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys
while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses
1997; 13:933–943.
71. Burkly L, Mulrey L, Blumenthal R, Dimitrov DS. Synergistic inhibition of human immunodeficiency
virus type 1 envelope glycoprotein-mediated cell fusion and infection by an
antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol 1995; 69:
4267–4273.
72. Chang YW, Sawyer LSW, Murthy KK, et al. Postexposure immunoprophylaxis of primary
isolates by an antibody to HIV receptor complex. Proc Natl Acad Sci USA 1999;
96:10367–10372.
73. Olson W, Nagashima K, Tran D, et al. HIV-1 and chemokine-inhibitory activities of anti-
CCR5 antibodies map to distinct CCR5 epitopes [Abstract]. In: Programs and Abstracts,
6th Conference on Retroviruses and Opportunistic Infections 1999; Chicago.
74. Murayama T, Cai Q, Rinaldo CR. Antibody-dependent cellular cytotoxicity mediated by
CD16 � lymphocytes from HIV-seropositive homosexual men. Clin Immunol Immunopathol
1990; 55:297–304.
75. Ahmad A, Morriset R, Thomas R, Menezes J. Evidence for a defect of antibodydependent
cellular cytotoxicity (ADCC) effector function and anti-HIV gp120/gp41specific
ADCC mediating antibody titers in HIV-infected individuals. J Acquir Immune
Defic Syndr 1994; 7:428–437.